Determination of related impurities in glimepiride tablets by the HPLC method
Keywords:glimepiride, tablets, quality control, diabetes mellitus type 2, HPLC, related impurities
Glimepiride is one of the modern and effective drugs that counteract diabetes mellitus type 2. Like other drugs glimepiride must comply with quality standards set by relevant government departments.
Aim. To determine the content of related impurities in glimepiride tablets in order to assess the drug quality.
Materials and methods. The study was performed by the reversed-phase HPLC with a spectrophotometric detector in the isocratic mode, in the UV-region of the spectrum. To determine impurities the method of comparison with the solution having the known concentration of impurities and the active substance was used.
Results and discussion. It has been shown that the drug contains ≤ 0.18 % of identified and unidentified impurities.
Conclusions. The purity of the drug complies with the requirements of normative documents.
Rasin, M. S. (2002). Vnutrishni khvoroby. Poltava: Formika, 345.
2. Derzhavna Farmakopeia Ukrainy (Second Ed., Vol. 1). (2015). Kharkiv: Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv, 1128.
Lukianchuk, E. (2015). Ezhenedelnik Apteka, 48, 1019. Available at: http://www.apteka.ua/article/350970
Basit, A., Riaz, M., Fawwad, A. (2012). Glimepiride: evidence–based facts, trends, and observations. Vascular Health and Risk Management, 8, 463–472. doi: 10.2147/vhrm.s33194
5. European Pharmacopoeia (Sixth Ed., Vol. 2). (2008). Nordlingen: Druckerei C. H. Beck, 1974.
6. Nakaz MOZ Ukrainy № 877 vid 19.08.2009. Pro zatverdzhennia Derzhavnoi tsilovoi prohramy «Tsukrovyi diabet». Available at : http://zakon4.rada.gov.ua/laws/show/877–2009–%D0%BF
7. Derzhavna naukovo–doslidna laboratoriia z kontroliu yakosti likarskykh zasobiv. Available at: http://www.druglab.kiev.ua/
Kahn, S. E., Cooper, M. E., Prato, S. D. (2014). Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. The Lancet – 383 (9922), 1068–1083. doi: 10.1016/S0140–6736(13)62154–6
Olokoba, A. B., Obateru, O. A., Olokoba, L. B. (2012). Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Medical Journal, 27 (4), 269–273. doi: 10.5001/omj.2012.68
Stefansson, E., Einarsdottir, A. B. (2015). Public health and prevention of blindness in diabetes. International Journal of Diabetes Mellitus, 3 (1), 1–3. doi:10.1016/j.ijdm.2011.01.011
Venkatasubramanian, R. T., Suresh, M. K., Sanjay, J. N., Sachin, B. G. (2006). WO 2006103690 A1. A novel process for preparation of substantially pure glimepiride; declared 18.05.2005; published 05.10.2006.
Zhu, H., Zhu, Sh., Zhang, X., Guo, Y., Shi, Y., Chen, Zh. (2013). Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta–analysis of randomized controlled trials. Diabetology & Metabolic Syndrome, 5, 70–74. doi: 10.1186/1758–5996–5–70
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).